Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Significant Accounting Policies (Tables)

v3.25.1
Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Significant Accounting Policies [Abstract]  
Schedule of Depreciable Rates of Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:

 

    %  

Mainly

%
         
Laboratory equipment   10   10
         
Computers, office furniture and equipment   6 - 33   33
Schedule of Major Customer Data as a Percentage of Total Revenues

Major customer data as a percentage of total revenues:

 

      Year ended December 31,  
      2024     2023     2022  
                     
  Cipher Pharmaceuticals (Canada)     7 %     11 %     11 %
  Chong Kun Dang Pharmaceuticals Corp. (South Korea)     11 %     25 %     25 %
  Gebro Holding GmbH (Austria)     11 %     18 %     18 %
  Ewopharma AG (Switzerland)     30 %     46 %     46 %
  Vetbiolix (France)     41 %     -       -  
                           
  Total     100 %     100 %     100 %
Schedule of Antidilutive Shares The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:
    Year ended December 31,  
    2024     2023     2022  
                   
Options     124,829,000       82,477,000       27,002,200  
Warrants     2,659,797,128       1,852,010,606       375,197,640  
                         
Total     2,784,626,128       1,934,487,606       402,199,840